Abstract

Purpose

We evaluated the impact of menopause-associated vasomotor symptoms (VMS) on sleep. We also sought to establish the content validity of Patient-Reported Outcomes Measurement Information System (PROMIS) short form Sleep-Related Impairment and Sleep Disturbance measures in postmenopausal women with moderate to severe VMS.

Methods

Cross-sectional, in-person, qualitative interviews were conducted in the United States (Texas, Illinois) and European Union (UK, France) with women aged 40–64 years experiencing moderate to severe VMS (≥35/wk). Main outcomes were impact of VMS on sleep based on concept elicitation and content validity of PROMIS Sleep-Related Impairment and Sleep Disturbance short forms via cognitive debriefing.

Results

Thirty-two women (US: n = 16; EU: n = 16) participated. A majority (US: 93.8%; EU: 93.8%) said VMS affected sleep; specifically, they had sleep interrupted by sweating or overheating and had difficulty returning to sleep. Sleep disturbance was the most bothersome aspect of VMS (US: 75%; EU: 50%). VMS-associated sleep disturbance affected next-day work productivity, mood, relationships, daily activities, concentration, social activities, and physical health. Participants found both PROMIS sleep measures relevant and easy to answer; the Sleep Disturbance measure was considered the most relevant. Participants had no difficulty remembering their experiences over the 7-day recall period and found the response options to be distinct.

Conclusion

VMS associated with menopause significantly interferes with sleep and next-day functioning (e.g., work productivity), supporting assessment of sleep outcomes in studies evaluating treatment of VMS. Women with moderate to severe VMS found that the PROMIS Sleep-Related Impairment and Sleep Disturbance short forms assessed constructs important to understanding sleep in the context of menopause-associated VMS.

Details

Title
Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep
Author
English, Marci 1   VIAFID ORCID Logo  ; Stoykova Boyka 2 ; Slota, Christina 3 ; Doward Lynda 4 ; Siddiqui Emad 2 ; Crawford, Rebecca 5 ; DiBenedetti Dana 3 

 Astellas Pharma Inc., Pharma Global Development, Northbrook, USA (GRID:grid.423286.9) (ISNI:0000 0004 0507 1326) 
 Astellas Pharma Inc., Surrey, UK (GRID:grid.468262.c) (ISNI:0000 0004 6007 1775) 
 RTI Health Solutions, Patient-Centered Outcomes Assessment Group, Research Triangle Park, USA (GRID:grid.416262.5) (ISNI:0000 0004 0629 621X) 
 RTI Health Solutions, Manchester, UK (GRID:grid.416262.5) 
 RTI Health Solutions, Manchester, UK (GRID:grid.468262.c) 
Publication year
2021
Publication date
Dec 2021
Publisher
Springer Nature B.V.
e-ISSN
25098020
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2535728526
Copyright
© The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.